Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density.

Détails

ID Serval
serval:BIB_1F4621B3259D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density.
Périodique
Lasers in Surgery and Medicine
Auteur(s)
Wang Y., Gonzalez M., Cheng C., Haouala A., Krueger T., Peters S., Decosterd L.A., van den Bergh H., Perentes J.Y., Ris H.B., Letovanec I., Debefve E.
ISSN
1096-9101 (Electronic)
ISSN-L
0196-8092
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
44
Numéro
4
Pages
318-324
Langue
anglais
Notes
Publication types: Evaluation Studies ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
BACKGROUND: Visudyne®-mediated photodynamic therapy (PDT) at low drug/light conditions has shown to selectively enhance the uptake of liposomal doxorubicin in subpleural localized sarcoma tumors grown on rodent lungs without causing morphological alterations of the lung. The present experiments explore the impact of low-dose PDT on liposomal doxorubicin (Liporubicin™) uptake to different tumor types grown on rodent lungs.
MATERIAL AND METHODS: Three groups of Fischer rats underwent subpleural generation of sarcoma, mesothelioma, or adenocarcinoma tumors on the left lung. At least five animals of each group (sarcoma, n = 5; mesothelioma, n = 7; adenocarcinoma, n = 5) underwent intraoperative low-dose (10 J/cm(2) at 35 mW/cm(2) ) PDT with 0.0625 mg/kg Visudyne® of the tumor and the lower lobe. This was followed by intravenous (IV) administration of 400 µg Liporubicin™. After a circulation time of 60 min, the tumor-bearing lung was processed for HPLC analyses. At least five animals per group underwent the same procedure but without PDT (sarcoma, n = 5; mesothelioma, n = 5; adenocarcinoma, n = 6). Five untreated animals per group underwent CD31 immunostaining of their tumors with histomorphometrical assessment of the tumor vascularization.
RESULTS: Low-dose PDT significantly enhanced Liporubicin™ uptake to all tumor types (sarcoma, P = 0.0007; mesothelioma, P = 0.001; adenocarcinoma, P = 0.02) but not to normal lung tissue compared to IV drug administration alone. PDT led to a significantly increased ratio of tumor to lung tissue drug uptake for all three tumor types (P < 0.05). However, the tumor drug uptake varied between tumor types and paralleled tumor vascular density. The vascular density was significantly higher in sarcoma than in adenocarcinoma (P < 0.001) and mesothelioma (P < 0.001), whereas there was no significant difference between adenocarcinoma and mesothelioma.
CONCLUSION: Low-dose Visudyne®-mediated PDT selectively enhances the uptake of systemically administered liposomal doxorubicin in tumors without affecting the drug uptake to normal lung. However, drug uptake varied significantly between tumor types and paralleled tumor vascular density.
Mots-clé
Adenocarcinoma/blood supply, Adenocarcinoma/drug therapy, Animals, Antibiotics, Antineoplastic/administration & dosage, Antibiotics, Antineoplastic/pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols, Cell Line, Tumor, Dose-Response Relationship, Drug, Doxorubicin/administration & dosage, Doxorubicin/pharmacokinetics, Liposomes, Lung Neoplasms/blood supply, Lung Neoplasms/drug therapy, Male, Mesothelioma/blood supply, Mesothelioma/drug therapy, Photochemotherapy, Photosensitizing Agents/administration & dosage, Photosensitizing Agents/therapeutic use, Porphyrins/administration & dosage, Porphyrins/therapeutic use, Rats, Rats, Inbred F344, Sarcoma/blood supply, Sarcoma/drug therapy, Treatment Outcome
Pubmed
Web of science
Création de la notice
05/05/2012 16:43
Dernière modification de la notice
20/08/2019 13:55
Données d'usage